Elevated baseline C-reactive protein predicts poorer survival in lung cancer: a 22-year retrospective cohort study
Xiaomin Wei, Xiaoyan Liu, Mei Li, Hanping Wang, Wei Zhong, Xiaotong Zhang, Xiaoxing Gao, Mengzhao Wang, Xuefei Wu, Meng Rui, Ruzetuoheti Yiminniyaze, Xiaoyan Si, Li Zhang · 2026
Read Elevated baseline C-reactive protein predicts poorer survival in lung cancer: a 22-year retrospective cohort study by Xiaomin Wei, Xiaoyan Liu, Mei Li, Hanping Wang, Wei Zhong, Xiaotong Zhang, Xiaoxing Gao, Mengzhao Wang, Xuefei Wu, Meng Rui, Ruzetuoheti Yiminniyaze, Xiaoyan Si, Li Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13263876.txt.
Description
Xiaomin Wei and colleagues mined in 2026 twenty-two years of records at one Beijing hospital to test whether a cheap inflammation blood test forecasts lung cancer survival. C-reactive protein rises with body-wide inflammation, which tumors can exploit. Their cohort held 1,339 newly diagnosed patients treated between 2000 and 2022, with levels drawn before any therapy.
Forty-one percent arrived with elevated levels, and they skewed older, male, more often smokers, and more often advanced in stage. Their median survival reached nineteen months against forty-four for patients with low levels. Five-year survival split just as starkly, near sixteen percent against thirty-seven. Adjustment for stage, fitness, and spread left the protein an independent predictor of both progression and death. The authors propose it as routine risk information hiding in a test clinics already run.
Catalog record
| CREATOR | Xiaomin Wei, Xiaoyan Liu, Mei Li, Hanping Wang, Wei Zhong, Xiaotong Zhang, Xiaoxing Gao, Mengzhao Wang, Xuefei Wu, Meng Rui, Ruzetuoheti Yiminniyaze, Xiaoyan Si, Li Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |